Endocyte Inc (ECYT.OQ)
14 Dec 2018
BRIEF-Endocyte - On Nov 30, Waiting Period With Respect To Filing Under Hart-Scott-Rodino Act Expired In Connection With Proposed Merger With Novartis AG
* ENDOCYTE SAYS ON NOV 30, 2018, WAITING PERIOD WITH RESPECT TO FILING UNDER HART-SCOTT-RODINO ACT EXPIRED IN CONNECTION WITH PROPOSED MERGER WITH NOVARTIS AG Source text: [https://bit.ly/2SogDFh] Further company coverage:
Oct 18 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:
ZURICH Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.
* Analysts say Q3 results take back seat to deal (Adds comments from CEO, shares, details throughout)
Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.
Oct 18 Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.
* NOVARTIS ANNOUNCES PLANNED ACQUISITION OF ENDOCYTE TO EXPAND EXPERTISE IN RADIOPHARMACEUTICALS AND BUILD ON COMMITMENT TO TRANSFORMATIONAL THERAPEUTIC PLATFORMS
Oct 18 Biopharmaceutical company Endocyte Inc said on Thursday that Novartis AG will acquire Endocyte in an all-cash deal for $24 per share, or a total equity value of about $2.1 billion.
* ENDOCYTE ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG FOR $2.1 BILLION